| Name | Title | Contact Details |
|---|
ValenTx was founded with the goal of treating some of the most pervasive health problems of our time: obesity and obesity-related metabolic disorders such as type-2 diabetes and hypertension. Our approach is to create a non-surgical, endoluminal bypass device that builds on the success of established medical interventions, resulting in a highly effective and least-invasive therapy. Current treatments for these diseases include surgery, pharmacology, and medically supervised lifestyle management. The risks, costs, and in some cases poor efficacy of these treatments have hampered their broad adoption by patients, physicians, and payers alike. A truly unmet clinical need exists for a therapy that can deliver the efficacy obtained through surgery, but without the risks and costs associated with surgical intervention. The ValenTx endoluminal bypass therapy mimics the attributes of a Roux-en-Y gastric bypass and is implanted through a non-surgical, endoscopic procedure. This procedure does not require gastric stapling or permanent changes to the patient`s anatomy. The device is removable, replaceable and designed so that the physician could change the therapeutic profile, thereby optimizing the treatment towards the individual patient`s needs. ValenTx has developed a strong intellectual property portfolio, which lies at the foundation of this therapy. The company has successfully conducted a series of clinical studies demonstrating the viability, safety, and efficacy of the therapy.
Drive DeVilbiss is committed to bringing to market a superior suite of products that focuses on innovation and design while improving the quality of life and promoting the independence for the individuals that use our durable medical equipment. Drive is dedicated to their customers by continually offering the highest quality and most functional products across a broad spectrum of health care needs, products that are a better value and competitively priced delivered by a team of world-class professionals. Drive’s complete line of products enhances the life of each user, from the mobility, bariatric, pressure prevention, self-assist, rehabilitation, pediatric products, to our wheelchairs, sleep surfaces, beds, respiratory equipment, power scooters, patient room equipment, to our electrotherapy devices and personal care products. We are the fastest growing global manufacturers of durable medical equipment; our products are used and distributed throughout North America, Europe, Central America, South America, the Middle East and Asia. Our market spans many verticals including: home healthcare providers, healthcare distributors, retailers, and e-tailers. Our recent expansion includes a new Long-Term Care Division and a new Acute Care Division. These developments are accompanied by the continued growth in the core home health care business. The corporate and distribution offices extend across the United States, Canada, United Kingdom, Germany, Romania, China and Taiwan.
MedVenture Technology dedicates resources to building a strong community. Employees passionate about a charitable organization are encouraged to share their enthusiasm at work. Volunteers are recruited, donations are accepted, and families all around us
CVRx® is a private company located in Minneapolis, Minnesota. The company has developed proprietary active implantable technology for the treatment of high blood pressure, also referred to as hypertension, and heart failure. The CVRx senior management and technical team have many years of experience commercializing implantable medical devices. The company is supported by an outstanding board of directors and a world-class scientific advisory board, which includes thought leading physicians and scientists in the field of hypertension and heart failure. CVRx has developed an implantable device that is designed to treat high blood pressure and heart failure. This new device called Barostim neo™ is designed to trigger the body`s own natural blood flow regulation system to treat high blood pressure and heart failure. CVRx has a strong intellectual property foundation, which will protect this unique technology. Barostim neo is CE marked in Europe for the treatment of hypertension patients. It is also CE marked in Europe for the treatment of heart failure. This product is currently under clinical evaluation in the United States and Canada for the treatment of high blood pressure and heart failure.
Core Oncology is a Santa Barbara, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.